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Rabies virus infects almost all mammals resulting in lethal disease. To date there is no treatment avail-
able for symptomatic rabies and there is an urgent need to develop treatment strategies that would pro-
long survival, thereby providing a window of opportunity for the host to mount a protective immune
response. We hypothesized that both virus and excessive immune response contribute to disease and
that interfering with both is necessary to prevent lethal disease. Here, we have inhibited the pro-
inflammatory response associated with pyroptosis and showed that inhibition of CASP-1 had a beneficial
effect on survival time. Our results confirm that some inflammatory responses may be involved in the
pathogenesis of severe disease and the results suggest that effective intervention includes inhibition of
virus and host response.
 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Short communication
Rabies encephalitis, caused by any of the Lyssaviruses is the
only known infectious disease causing almost 100% mortality to
infected individuals. Despite the availability of effective vaccines
and the possibility to protect against infection by post-exposure
treatment, rabies still accounts for almost 60,000 deaths annually
mainly affecting children and young adults in the resource-poor
countries [1].
Once neurological symptoms appear in infected individuals
only palliative care can be given and death is inevitable. In
developed countries sporadic cases are reported, and patients will
be typically admitted to intensive care units and put under induced
coma, which allows physicians to test experimental treatment
protocols. To date, little success has been achieved with such
experimental treatments [2].Monoclonal antibodies and hyperimmune serum have been
given intrathecally to rabies patients in an attempt to control infec-
tion with passive transfer of antibodies at the site of infection.
Alternatively, antivirals such as ribavirin have been used with no
improvement in clinical course of disease [3]. The mechanisms of
recovery reported in the few patients that have survived clinical
rabies are not understood but the hypothesis is that the immune
system of the patients cleared the virus [4]. For instance, survivors
developed virus neutralizing antibodies, which could have limited
the amount of virus, allowing the innate immune response to fur-
ther inhibit or clear the infection. It is hypothesized that cell death
due to virus replication and host responses triggered as a result of
virus replication both play a role in the pathogenesis of severe
rabies. It is clear that neutralizing antibodies are the principal
modality of protective immunity. However, the role of innate and
T cell immunity in clearing RABV from the CNS or pathogenesis
are still poorly understood [5].
Rabies virus (RABV) is an exclusively neurotropic virus that
inhibits an efficient interferon antiviral response, but there is no
evidence that the virus causes cell death such as necrosis or apop-
tosis of infected neurons. The role of the inflammatory response iss://doi.
Fig. 1b. RABV antigen was detected in all mice that succumbed to rabies in
formalin fixed brain tissues after intramuscular inoculation with SHBRV-18.
Antigen was detected in all areas of the brain (cerebellum, cortex, brain stem)
and in the spinal cord (see Ref. [7] for detailed method description). One
representative picture from a positive cerebellum from a BALB/c mice is shown
here.
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2 P. Koraka et al. / Vaccine xxx (2018) xxx–xxxcontradicting since in some lethal cases of rabies, severe inflamma-
tion was observed and in some cases no evidence of inflammation
was reported [6,7]. Experimental infection in mice also supports
the notion that rabies infection is not associated with an overt
inflammatory response. Previous studies in our laboratory have
demonstrated the activation of pyroptosis during RABV infection
[18]. Pyroptosis is an inflammation-induced form of cell death. In
this study we investigated whether pyroptosis is a relevant patho-
genic mechanism in the mouse model and whether inhibition of
pyroptosis could mitigate rabies disease in mice.
Adult female mice of different genetic backgrounds (BALB/c,
C57BL/6) were infected via the intramuscular route in the right
hind leg with a lethal dose of wild type silver-haired bat rabies
virus (SHBRV-18, 106TCID50/mouse; a kind gift of Dr. B. Dietzhold,
Jefferson University, USA). Control mice were inoculated with an
equivalent dose of betapropiolactone (BPL)-inactivated virus. Mice
were monitored for clinical signs of rabies and killed by euthanasia
when humane end-points were reached (ruffled hair, hunched
back and hind-leg paralysis) (Fig. 1a). Virus infection was con-
firmed with detection of infectious virus in brain samples and
RABV antigen in formalin -fixed brain tissue as previously
described [8] (Fig. 1b).
To demonstrate activation of the pyroptotic pathway during
RABV infection in mice, we tested for up-regulation of key mole-
cules of pyroptosis (Caspase-1, IL-1b and IL-18) on the mRNA level
in brain samples. Briefly, brain samples were collected at the time
of euthanasia from SHBRV-18-infected mice, weighted and stored
as 10% homogenate in DMEM medium (Lonza, Basel, Switzerland)
with 10% penicillin and streptomycin (Lonza) at 80 C. RNA was
isolated using the MagNA Pure LC 1.0 system and High Pure RNA
isolation kit (Roche, Mannheim, Germany) according to the manu-
facturer’s procedures and quantified using NanoDrop ND-1000
UV–VIS spectrophotometer (NanoDrop Technologies, Wilmington,
USA). mRNA was transcribed to cDNA using Oligo(dT)12-18 Primer
(Invitrogen, Carlsbad CA, USA) and Superscript III reverse transcrip-
tase (Invitrogen) according to the instructions of the manufacturer.
Gene expression was quantified using commercially available Taq-
Man Gene Expression Assays of the respective genes (Applied
Biosystems, Foster City CA, USA) and TaqMan Universal PCR Mas-
ter Mix (Applied Biosystems). Transcript numbers were expressed
as relative to the housekeeping gene b–actin (Applied Biosystems)
following the formula 2DCt ⁄ 105 [9] where DCt = Ctgene of interest 
Ctb–actin and were corrected for RNA quantity. As shown in Fig. 2, in
both mouse strains, CASP-1 and IL-1bwere significantly elevated in
mice that had received infectious virus compared to the mice that
received BPL-inactivated virus (P < 0.05; Mann-Whitney, non-
parametric test). IL-18 was significantly elevated only in C57BL/6
mice that received infectious virus (P = 0.004).0 5 10 15 20 25
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Fig. 1a. Survival curves of BALB/c and C57BL/6 mice after intramuscular inoculation
of 106 TCID50 of SHBRV-18 virus.
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Fig. 2. Upregulation of pyroptotic markers after infection with SHBRV-18 of BALB/c
(upper panel) or C57BL/6 mice. d: CASP-1, j: IL-1b, r: IL-18. Open symbols
represent mRNA levels of the respective markers in mice that received BPL-
inactivated virus. Statistical differences were calculated with a two-tailed Mann-
Whitney test *: p < 0.05, **: p < 0.01, ns: not statistically different.
Please cite this article in press as: Koraka P et al. Inhibition of caspase-1 prolon
org/10.1016/j.vaccine.2018.04.002Pyroptosis, an essentially pro-inflammatory pathway of cell
death could be responsible not only of neuronal loss during rabies
but also neuronal dysfunction as has been described for other neu-
rodegenerative diseases [10]. Since mRNA of key pyroptotic mole-
cules was up-regulated in SHBRV-18 infected mice, we sought togs survival of mice infected with rabies virus. Vaccine (2018), https://doi.
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P. Koraka et al. / Vaccine xxx (2018) xxx–xxx 3investigate the effect of pyroptotic inhibitors on the course of clin-
ical rabies in the C57BL/6 mouse model. Groups of 8-week-old
female C57BL/6 mice (n = 10) were inoculated intramuscularly in
the right hind leg with 106 TCID50/mouse of SHBRV-18 virus. Five
days after inoculation, treatment was initiated with CASP-1 inhibi-
tor (100 ng/mouse of Ac-YVAD-cmk (InvivoGen, Toulouse, France))
or IL-1b inhibitor (200 mg/mouse of Kineret, Sobi Inc., Stockholm,
Sweden). Treatment was given intracranially in 10 ml volume on
days 5, 7 and 9 post infection. Control mice (n = 7 per group)
received PBS instead of infectious virus on day 0 and the same
treatments as infected mice on days 5, 7 and 9. Ten mice received
only infectious virus and three mice received only PBS intracra-
nially on day 5, 7 and 9.
All virus-infected mice succumbed to rabies within two weeks
post infection and virus was isolated from all infected mice (trea-
ted and non-treated). As expected, viral titers in the brain and
spinal cord did not differ between treated and non-treated mice
(Fig. 3) since the inhibitors used in this study would not influence
viral replication. As shown in Fig. 4a, inhibition of CASP-1 signifi-
cantly prolonged median survival time for 1.5 days compared to
non-treated mice (p = 0.0371, Log-rank Mantel-Cox test). On the
mRNA level, all key molecules of pyroptosis were suppressed to
nearly baselines levels (CASP-1 and IL1b) or even lower (IL-18)
compared to infected mice that did not receive treatment
(Fig. 4b). Only TNF-a was not completely suppressed to baseline
levels, indicating that additional to pyroptosis, more inflammatory
pathways are likely to be activated during rabies. Inhibition of IL-
1b did not have a significant effect on survival of infected mice
compared to non-treated mice (Fig. 4a, p = 0.146, Log-rank
Mantel-Cox test). However, Kineret suppressed the expression
of CASP-1 and IL-1b to baseline levels whereas IL-18 expression
was down-regulated to even lower than baseline levels (Fig. 4b).
Similarly to the group of mice that received Ac-YVAD-cmk, theA 
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Fig. 3. Infectious viral titers recovered from mice that were euthanized when
reached humane end points of rabies virus infection in (A) the brain and (B) spinal
cord. Green: SHBRV-18 infected mice that received Ac-YVAD-cmk treatment, red:
SHBRV-18 mice that received kineret and blue: non-treated SHBRV-18 infected
mice. (For interpretation of the references to colour in this figure legend, the reader
is referred to the web version of this article.)
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Fig. 4. Inhibition of pyroptosis in SHBRV-18 infected C57BL/6 mice. (a) survival
curves after infection and treatment of mice with the respective molecules. (b)
mRNA levels of key pyroptotic markers in mice treated with the respective
molecules. Open symbols represent the groups of mice that received treatment only
(no virus infection). Red symbols represent the group of mice that received SHBRV-
18 only and no treatment and green symbols represent the group of mice that
received PBS instead of virus or treatment and are considered baseline values for
the respective molecules. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
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org/10.1016/j.vaccine.2018.04.002Kineret group had reduced expression of TNF-a compared to
non-treated mice but not as low as baseline levels.
Mouse brains were formalin fixed, paraffin embedded and
stained with hematoxylin-eosin for histological examination.
Histopathological screening of the brains that were collected from
the mice revealed that infected animals had minor visible abnor-
malities. Occasionally, multifocal mild to moderate lymphocytic
meningoencephalitis was seen. Neither cytoplasmic eosinophilic
inclusion bodies (Negri bodies) nor necrosis were seen. However,
virus antigen was detected in the brains of infected mice as previ-
ously described [8]. Based on morphological criteria, virus antigen
expression was restricted to neurons. Virus antigen was seen as
3- to 5-lm-diameter red granules, mostly in the cytoplasm of neu-
ronal cell bodies, but also arranged in narrow rows in neuronalgs survival of mice infected with rabies virus. Vaccine (2018), https://doi.
4 P. Koraka et al. / Vaccine xxx (2018) xxx–xxxprocesses. Occasionally rabies-antigen positive neurons showed
signs of degeneration as demonstrated by loss of Nissl substance
with shrinkage. Karyopyknosis and karyorrhexis without infiltra-
tion of inflammatory cells was present, although not abundant.
To evaluate the effect of treatment on the number and distribu-
tion of neurons expressing virus antigen, we compared virus anti-
gen expression in 12 selected areas of the brain (Table 1). To
exclude the time of death as a factor determining virus distribution
we only looked in mice that were euthanized at day 8 post inocu-
lation. For this time point we only had one mouse each in the virus
control and Ac-YVAD-cmk treated groups and two mice from the
Kineret treated group.
The general trend at day 8 p.i. was that primary and secondary
motor areas in layer 5 and the motor area of the midbrain were the
most affected since RABV antigen-positive neurons were abun-
dantly detected in these areas. In contrast, scarce positive neurons
were seen in the hippocampus, the caudoputamen, and the sensory
related colliculi of the midbrain.
To rule out the possibility that a lower proportion of virus-
positive neurons was due to virus-induced loss of neurons, neurons
were stained with a neuron marker (NeuN), and the total number
of neurons in two areas with abundant infection (primary and sec-
ondary motor area layer 5) was compared between infected and
non-infected mice. There were no significant (P > 0.05) differences
in the number of neurons between infected and non-infected mice
(Mann-Whitney non parametric t-test, data not shown).
Only supportive care to mitigate the severe symptoms can be
offered to rabies victims until coma and death occur. A small num-
ber of patients (n = 5) have recovered from rabies with severe neu-
rological sequelae [11]. Therefore, any treatment that could
increase the chances of survival or improve the clinical course of
rabies would be beneficial to the thousands of rabies patients.
The use of classical antiviral approaches has proven unsuccessful
for rabies [2]. In this study, we have shown that therapy, focusing
on inhibition of the host response rather than the virus might be
useful to treat rabies.Table 1
Virus distribution and abundance (0–5) score of mice that died on day 8.
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org/10.1016/j.vaccine.2018.04.002Pyroptosis, an essentially proinflammatory pathway of cell
death could be responsible not only of neuronal loss during rabies
but also has a detrimental effect on neuronal function with the
release of pro-inflammatory cytokines. Pyroptosis was shown to
be triggered by for instance chikungunya virus and HIV [12]. We
have shown that intervention early in the pyroptotic pathway
(inhibition of CASP-1) can prolong survival of mice, whereas inter-
vention with downstream products of the activated pathway (inhi-
bition of IL-1b) did not influence survival time of mice. Since these
molecules act as host response modulators rather than antivirals,
infectious virus titers were not influenced by the treatment
approach suggesting that prolongation of survival in the Ac-
YVAD-cmk treated group was indeed due to inhibition of some of
the pro-inflammatory pathway and not due to interference with
viral replication. Nevertheless, all mice eventually succumbed to
rabies, indicating that treatment with CASP-1 inhibitor alone is
not sufficient to completely abolish detrimental inflammatory host
responses. It is possible that additional inflammatory pathways
activated during rabies contribute to pathogenesis and therefore,
a combination of different host-response inhibitors might increase
the chance of survival after rabies. In addition, inhibiting virus
replication as well as host responses might be more beneficial than
focusing on host response only.
Our observations that inhibition of CASP-1 could prolong sur-
vival time of mice could have been an effect of timing. It is gener-
ally accepted that once symptoms occur in rabies patients then
death is inevitable. Therefore, in our study we chose to treat mice
only at the moment that we observed signs of rabies and not ear-
lier. In our mouse model, there is only a short window of virus
being present in the brain and development of signs (typically less
than 12 h). It is therefore possible that treatment with CASP-1 inhi-
bitor started too late to be able to control the disease. In addition,
within our study protocol, we choose to intervene only for a short
period of time (three intracranial inoculations every other day). It
is possible that survival rates could have increased if treatment
was given more often or for longer period of time. In addition,Avera
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P. Koraka et al. / Vaccine xxx (2018) xxx–xxx 5repeated injection of the respective drugs intracranially may have
contributed to death of the animals and administration of drugs
parentally would be the preferred route.
It should be noted that our observations should be interpreted
with caution. We have used the mouse model to demonstrate
the presence of excessive host response that could have a detri-
mental effect on clinical outcome. However, this remains a model
to study disease and the observed responses to infection may be
species dependent or even virus strain dependent. For instance,
inflammatory response in the brains of dogs infected with rabies
virus were subtle [13] whereas mice had different transcriptomic
profile when infected with attenuated or highly pathogenic rabies
virus [7]. Earlier studies have suggested that immune-mediated
cell death, may differ between animal species and inflammatory-
immune response accounted for early death in rabies [14–17].
Nevertheless, we have used transcriptomic data to identify path-
ways that could play a role in pathogenesis of rabies in mice [18]
and tailor our proposed intervention strategies to mRNA profiles.
In conclusion, we consider these preliminary experiments
promising for the design of innovative treatment strategies against
rabies. We propose that CASP-1 inhibition should be included in
future designs of combination therapy, given more frequently to
increase the chances of survival during rabies.
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